Albion Financial Group Fate Therapeutics Inc Transaction History
Albion Financial Group
- $1.48 Billion
- Q2 2025
A detailed history of Albion Financial Group transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Albion Financial Group holds 225 shares of FATE stock, worth $211. This represents 0.0% of its overall portfolio holdings.
Number of Shares
225
Previous 225
-0.0%
Holding current value
$211
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding FATE
# of Institutions
148Shares Held
94.9MCall Options Held
46.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$12.1 Million1.07% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$8.24 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$7.33 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$4.03 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $91.2M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...